<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093064</url>
  </required_header>
  <id_info>
    <org_study_id>208083</org_study_id>
    <nct_id>NCT03093064</nct_id>
  </id_info>
  <brief_title>Inflammatory Response In Schizophrenia</brief_title>
  <acronym>IRIS</acronym>
  <official_title>The Role of Inflammation in Brain and Cognitive Function in Mental Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South London and Maudsley NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia affects a significant proportion of the population and current levels of&#xD;
      understanding of the illness is inadequate to treat it effectively. Converging lines of&#xD;
      evidence suggest that neuroinflammation occurs in schizophrenia, and specifically&#xD;
      over-activity of brain-resident immune cells called microglia. It is however unclear whether&#xD;
      activated microglia play a primary role in schizophrenia, or whether this is a secondary&#xD;
      phenomenon of no pathophysiological significance. The investigators therefore plan to test&#xD;
      the effect of a monoclonal antibody (natalizumab) on psychotic symptoms in a cohort of first&#xD;
      episode psychosis patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an experimental medicine study, the purpose of which is provide a mechanistic understanding of neuroinflammation in schizophrenia by investigating response to natalizumab (phase 1b).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Translocator Protein (TSPO) availability pre- and post-natalizumab or placebo administration</measure>
    <time_frame>Baseline TSPO availability will be assessed at day -14 prior to first administration of natalizumab/placebo (day zero). TSPO availability will be re-assessed post administration of natalizumab/placebo at day +57(+14 days)</time_frame>
    <description>TSPO availability assessed using Positron Emission Tomography (PET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of TSPO availability with brain functional measures at baseline.</measure>
    <time_frame>Baseline combined PET/MRI scan will be performed at day -14 prior to administration of natalizumab/placebo (day zero)</time_frame>
    <description>Both TSPO availability (as measured using PET imaging) and brain functional measures (as measured using functional magnetic resonance imaging and magnetic resonance spectroscopy) will be measured simultaneously using a combined PET/MRI scanner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of cerebrospinal fluid (CSF) inflammatory markers with brain functional measures at baseline.</measure>
    <time_frame>Baseline PET/MRI scan will be performed at day -14 prior to administration of natalizumab/placebo (day zero). CSF collection will be performed between the time points day -14 to day -1 prior to administration of natalizumab/placebo (day zero).</time_frame>
    <description>Brain functional measures assessed using functional magnetic resonance imaging and magnetic resonance spectroscopy.&#xD;
CSF inflammatory markers: measurements of cytokine concentrations (e.g. C-reactive protein, Interleukin-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of blood inflammatory markers with brain functional measures at baseline.</measure>
    <time_frame>Baseline PET/MRI scan will be performed at day -14 prior to administration of natalizumab/placebo (day zero). Blood collection will be performed between the time points day -14 to day -1 prior to administration of natalizumab/placebo (day zero).</time_frame>
    <description>Brain functional measures assessed using functional magnetic resonance imaging and magnetic resonance spectroscopy.&#xD;
Blood inflammatory markers: measurements of cytokine concentrations (e.g. C-reactive protein, Interleukin-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in TSPO availability correlated with longitudinal change in brain functional measures.</measure>
    <time_frame>Baseline combined PET/MRI scan will be performed at day -14 prior to administration of natalizumab/placebo (day zero). Repeat combined PET/MRI scan will be performed at day +57(+14 days).</time_frame>
    <description>Both TSPO availability (as measured using PET imaging) and brain functional measures (as measured using functional magnetic resonance imaging and magnetic resonance spectroscopy) will be measured simultaneously using a combined PET/MRI scanner. There will be two separate scans - before and after administration of natalizumab/placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Patient Group: Natalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 300mg, intravenous, once monthly, total of 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Group: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline, intravenous, once monthly, total of 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natalizumab</intervention_name>
    <description>Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule Î±4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.</description>
    <arm_group_label>Patient Group: Natalizumab</arm_group_label>
    <other_name>Tysabri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo: normal saline</intervention_name>
    <description>Normal saline, intravenous infusion</description>
    <arm_group_label>Patient Group: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Aged 18-50 years&#xD;
&#xD;
          2. Diagnosis of schizophrenia or other psychotic disorder (Diagnostic and Statistical&#xD;
             Manual of Mental Disorders-5 (DSM-5);&#xD;
&#xD;
          3. Symptomatic, defined as one or more positive symptom &gt;3 AND one or more negative&#xD;
             symptom &gt;3 on the Positive and Negative Syndrome Scale (PANSS);&#xD;
&#xD;
          4. No acute relapse and psychiatrically stable for &gt;1 month before screening;&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. History of significant co-morbid CNS disorder (including significant head trauma or&#xD;
             significant loss of consciousness, Parkinson's Disease, Epilepsy, Alzheimer's&#xD;
             Dementia, Huntington's Disease).&#xD;
&#xD;
          2. Any absolute contraindications to natalizumab, as per natalizumab SPC&#xD;
&#xD;
          3. Current or recent (last 3 months) infection, or history of significant infection, or&#xD;
             an immunocompromised state&#xD;
&#xD;
          4. Previous use of natalizumab or previous use of other monoclonal antibody.&#xD;
&#xD;
          5. Ongoing long-standing use of oral steroids or non-steroidal anti-inflammatory drugs.&#xD;
&#xD;
          6. Pregnancy and/or breast-feeding.&#xD;
&#xD;
          7. Substance dependence/abuse other than to cigarettes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver D Howes</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiago Marques, MD, PhD</last_name>
    <phone>+44 207 848 0728</phone>
    <email>tiago.marques@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuya Mizuno, MD, PhD</last_name>
    <phone>+44 207 848 0434</phone>
    <email>yuya.mizuno@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Psychiatry, Psychology and Neuroscience, King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuya Mizuno, MD, PhD</last_name>
      <phone>+44 207 848 0434</phone>
      <email>yuya.mizuno@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

